Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...
The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t ...
American Cancer Society: “What causes non-small cell lung cancer?” “Oncogenes and tumor suppressor genes.” National Institutes of Health Genetics Home Reference: “Lung cancer.” ...
Lung cancer is the third most common cancer and the leading cause of cancer-related deaths in the U.S., and according to the ...
This study suggests that immunotherapy may not be the optimal ... New, Rare Type of Small Cell Lung Cancer Identified Sep. 11, 2024 — A team of doctors and researchers have identified a new ...
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
Whilst a persistent cough and coughing up blood is a sign something is wrong, another symptom that's often forgotten about is ...
The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...
More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery. Amivantamab's role in non–small cell lung ...
Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback